MediWound reiterates 2026 revenue guidance at $24-$26M

MediWound has reaffirmed its full-year 2026 revenue guidance of $24 million to $26 million, while also outlining a clinical timeline that officials said could shape the company’s near-term commercial outlook. The update was discussed during the company’s Q2 2026 investor call, officials said.

Officials also said key Phase III clinical milestones for EscharEx are expected by Q1 2027. They added that reactions to the update were still pending.

EscharEx timeline points to Q1 2027 milestones According EscharEx timeline points to Q1 2027 milestones According to officials According to officials, MediWound expects the next major Phase III milestones for EscharEx to occur by Q1 2027. The company framed that schedule as a factor that may influence assumptions about a near-term commercial ramp, depending on how the program progresses within that window. Officials said investors should watch for formal milestone updates or data readouts by March 31, 2027. They described any confirmation of Phase III progress on or before that date as the next potentially material event for the equity. Operational supports cited: Vericel agreement and manufacturing access On the operational side, officials pointed to a master services agreement with Vericel as part of the program’s support structure. They also cited access to NexoBrid manufacturing capacity as another operational enabler for the EscharEx Phase III effort.

Officials said manufacturing arrangements and external supply access are among the factors that could influence program readiness. They also said these elements can affect assumptions tied to potential commercial ramp planning, without providing further quantified detail.

2026 guidance reiterated, with limited additional revenue detail Officials reiterated that the company’s 2026 revenue guidance remains $24 million to $26 million and characterized the outlook as unchanged despite ongoing clinical activity. The company did not provide additional standalone revenue details on the call, officials said.

The update leaves the revenue range intact while placing attention on the EscharEx Phase III timeline and the operational arrangements referenced by management. Further clarity, officials said, is expected to come through milestone communications or data-related updates ahead of the March 31, 2027 timeframe.